BSX vs KVYO · P/E 20, rev $10.65B vs rev $1.23B
Boston Scientific Corp (BSX) versus Klaviyo, Inc. (KVYO) — a side-by-side from cached financials, not a winner call.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Klaviyo, Inc. (KVYO) is a software - infrastructure company listed on US.
Latest reported BSX revenue for 2026-06-30 was $10.65B. Net income was $2.24B. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Latest reported KVYO revenue for 2025-12-31 was $1.23B. Net income was -$31.8M. Revenue was up 31.6% from 2024-12-31 to 2025-12-31. KVYO currently screens at market cap $9.88B.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. KVYO currently screens at market cap $9.88B.
Not investment advice. Open the BSX and KVYO stock pages for the full models.
Not investment advice.